M R McClung

Summary

Publications

  1. ncbi Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, Portland, Oregon, USA
    Ann Med Interne (Paris) 151:392-8. 2000
  2. ncbi Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
    M R McClung
    Oregon Osteoporosis Center and Providence Medical Center, Portland 97213, USA
    N Engl J Med 344:333-40. 2001
  3. ncbi Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis
    M R McClung
    Oregon Osteoporosis Center, Portland 97213, USA
    Bone 19:195S-198S. 1996
  4. ncbi Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:293-9. 2013
  5. ncbi Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 23:267-76. 2012
  6. ncbi Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:227-35. 2013
  7. ncbi Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:301-10. 2013
  8. ncbi Blood pressure and calcium intake are related to bone density in adult males
    J A Metz
    Department of Medicine, Oregon Health Sciences University, Portland, USA
    Br J Nutr 81:383-8. 1999
  9. ncbi Bisphosphonates in osteoporosis: recent clinical experience
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 651, Portland, Oregon, USA
    Expert Opin Pharmacother 1:225-38. 2000

Detail Information

Publications9

  1. ncbi Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, Portland, Oregon, USA
    Ann Med Interne (Paris) 151:392-8. 2000
    ..Assessing risk factors for both osteoporosis and for fractures allows clinicians to identify individuals for whom these therapies are most appropriate...
  2. ncbi Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
    M R McClung
    Oregon Osteoporosis Center and Providence Medical Center, Portland 97213, USA
    N Engl J Med 344:333-40. 2001
    ..Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known...
  3. ncbi Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis
    M R McClung
    Oregon Osteoporosis Center, Portland 97213, USA
    Bone 19:195S-198S. 1996
    ..The effectiveness of bisphosphonates in combination with estrogen or bone growth stimulators also requires evaluation, and the extended long-term safety of these drugs must be determined...
  4. ncbi Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:293-9. 2013
    ..This adds to the range of risedronate dosing options and provides an alternative for patients who prefer once-a-month dosing...
  5. ncbi Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 23:267-76. 2012
    ..Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy...
  6. ncbi Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:227-35. 2013
    ..Denosumab treatment was well tolerated throughout the 8-year study...
  7. ncbi Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:301-10. 2013
    ..Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance...
  8. ncbi Blood pressure and calcium intake are related to bone density in adult males
    J A Metz
    Department of Medicine, Oregon Health Sciences University, Portland, USA
    Br J Nutr 81:383-8. 1999
    ..Future studies are needed to determine whether elevated blood pressure is causally related to the development of low bone mass, and what role dietary Ca plays in that pathway...
  9. ncbi Bisphosphonates in osteoporosis: recent clinical experience
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 651, Portland, Oregon, USA
    Expert Opin Pharmacother 1:225-38. 2000
    ....